Toxin peptide therapeutic agents

Details Toxin peptide therapeutic agents Toxin peptide therapeutic agents

2006-04-17

2010-11-16

Desai, Anand U (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000

Reexamination Certificate

active

07833979

ABSTRACT:
Disclosed is a composition of matter of the formulain-line-formulae description="In-line Formulae" end="lead"?(X1)a—(F1)d—(X2)b—(F2)e—(X3)c  (I)in-line-formulae description="In-line Formulae" end="tail"?and multimers thereof, in which F1and F2are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

REFERENCES:
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4906159 (1990-03-01), Sabo et al.
patent: 4911916 (1990-03-01), Cleary et al.
patent: 4925677 (1990-05-01), Shah et al.
patent: 4994439 (1991-02-01), Longenecker et al.
patent: 5023084 (1991-06-01), Chien et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5171264 (1992-12-01), Merrill et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5397702 (1995-03-01), Cahalan et al.
patent: 5446090 (1995-08-01), Harris et al.
patent: 5460820 (1995-10-01), Ebert et al.
patent: 5494895 (1996-02-01), Garcia et al.
patent: 5516523 (1996-05-01), Heiber et al.
patent: 5605702 (1997-02-01), Teillaud et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5714142 (1998-02-01), Blaney et al.
patent: 5739208 (1998-04-01), Harris et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5763478 (1998-06-01), Baker et al.
patent: 5783208 (1998-07-01), Venkateshwaran et al.
patent: 5792451 (1998-08-01), Sarubbi et al.
patent: 5827655 (1998-10-01), Chandy et al.
patent: 5900461 (1999-05-01), Harris et al.
patent: 5919455 (1999-07-01), Greenwald et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5990237 (1999-11-01), Bentley et al.
patent: 6077680 (2000-06-01), Kem et al.
patent: 6096891 (2000-08-01), Carr et al.
patent: 6245740 (2001-06-01), Goldenberg et al.
patent: 6267964 (2001-07-01), Nygren et al.
patent: 6273086 (2001-08-01), Ohki et al.
patent: 6342225 (2002-01-01), Jones et al.
patent: 6451986 (2002-09-01), Pettit
patent: 6548644 (2003-04-01), Pettit
patent: 6551821 (2003-04-01), Kandel et al.
patent: 6552170 (2003-04-01), Thompson et al.
patent: 6602498 (2003-08-01), Shen
patent: 6610281 (2003-08-01), Harris
patent: 6660843 (2003-12-01), Feige et al.
patent: 6689749 (2004-02-01), Lebrun et al.
patent: 6703485 (2004-03-01), Kandel et al.
patent: 6740743 (2004-05-01), Herrmann et al.
patent: 6768002 (2004-07-01), Herrmann et al.
patent: 6818418 (2004-11-01), Lipovsek et al.
patent: 6849714 (2005-02-01), Bridon et al.
patent: 6861405 (2005-03-01), Desir et al.
patent: 6887470 (2005-05-01), Bridon et al.
patent: 6892728 (2005-05-01), Helgesson et al.
patent: 6894025 (2005-05-01), Harris
patent: 6900317 (2005-05-01), Trunk et al.
patent: 6905688 (2005-06-01), Rosen et al.
patent: 6926898 (2005-08-01), Rosen et al.
patent: 6932962 (2005-08-01), Bäckstrom et al.
patent: 6946134 (2005-09-01), Rosen et al.
patent: 6989365 (2006-01-01), Fleer et al.
patent: 7005436 (2006-02-01), Lloyd et al.
patent: 7348004 (2008-03-01), Peters et al.
patent: 7381408 (2008-06-01), Mezo et al.
patent: 7404956 (2008-07-01), Peters et al.
patent: 2003/0069170 (2003-04-01), Soltero et al.
patent: 2003/0069395 (2003-04-01), Sato et al.
patent: 2004/0121959 (2004-06-01), Boone et al.
patent: 2005/0054570 (2005-03-01), Rosen et al.
patent: 0 219 716 (1987-04-01), None
patent: 0 473 084 (1991-08-01), None
patent: 0 668 353 (1995-08-01), None
patent: 0 668 354 (1995-08-01), None
patent: 0 575 545 (2003-05-01), None
patent: WO 88/06451 (1988-09-01), None
patent: WO 92/02634 (1992-02-01), None
patent: 9503065 (1995-02-01), None
patent: WO 95/13312 (1995-05-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/11953 (1996-04-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 98/23639 (1998-06-01), None
patent: WO 99/24055 (1999-05-01), None
patent: WO 99/38008 (1999-07-01), None
patent: WO 00/38651 (2000-07-01), None
patent: WO 00/69900 (2000-11-01), None
patent: WO 01/83525 (2001-11-01), None
patent: WO 02/11801 (2002-02-01), None
patent: WO 02/098446 (2002-12-01), None
patent: WO 02/100248 (2002-12-01), None
patent: WO 2004/017918 (2004-03-01), None
patent: WO 2004/017918 (2004-03-01), None
patent: WO 2004/043396 (2004-05-01), None
patent: WO 2004/110472 (2004-12-01), None
patent: WO 2005/047337 (2005-05-01), None
patent: WO 2006/002850 (2006-01-01), None
patent: 2006036834 (2006-04-01), None
patent: WO 2006/042151 (2006-04-01), None
Brantly, M., “Alpha1-Antitrypsin: Not Just an Antiprotease”, Am. J. Respir. Cell Mol. Biol. 27: 652-654 (2002).
Norton et al., “Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases”, Current Medicinal Chemistry 11: 3041-3052 (2004).
Caliceti, et al. ‘Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates,’Adv. Drug Del. Rev.,55: 1261-1277 (2003).
Norton, et al. ‘Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases,’Curr. Medic. Chem.,11: 3141-3152 (2004).
Wang, et al. ‘Polyethylene Glycol-modified Chimeric Toxin Composed of Transforming Growth Factor α andPseudomonasExotoxin,’Cancer Research,53: 4588-4594 (1993).
Bednarek et al., “Chemical synthesis and structure-function studies of margatoxin, a poten inhibitor of voltage-dependent potassium channel in human T lymphocytes”, Biochemical and Biophysical Research Communications, 198(2): 619-625, (1994).
Judge et al., “Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment”, Pharmacology and Therapeutics, Elsevier, GB, 111(1): 224-259, (2006).
Legros, et al., “Influence of a NH2-terminal extension on the activity of KTX2, a K<+> channel blocker purified fromAndroctonus australisscorpion venom”, FEBS Letters, Elsevier, Amsterdam, NL, 417(1): 123-129, (1997).
Tytgat, J. et al., “A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies”, Trends in Pharmacological Sciences, Elsevier, Haywarth, GB, 20(11): 444-447, (1999).
Beeton et al., “Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis”, PNAS, 98(24): 13942-13947 (2001).
Beeton et al., “The D-Diastereomer of ShK toxin selectively blocks voltage-gated k+ channels and inhibits T lymphocyte proliferation”, J of Biological Chemistry, 283(2): 988-997 (2008).
Brown, Larry, “Commercial challenges of protein drug delivery”, Expert Opin. Drug D

Affiliated with

Also associated with

Rating

Toxin peptide therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Toxin peptide therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Toxin peptide therapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4157879